Fortress Biotech, Inc. (FBIO)Healthcare | Biotechnology | Bay Harbor Islands, United States | NasdaqCM
2.36 USD
+0.01
(0.426%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.37 +0.01 (0.331%) ⇧ (April 17, 2026, 5:44 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:10 p.m. EDT
FBIO is a high-risk, high-reward stock with significant volatility and a lack of consistent dividends. The recent news highlights both positive developments and setbacks, which can lead to large price swings. The fundamental data shows a negative forward PE and low profitability, indicating potential for growth but with substantial risk. Short-term traders may look for momentum opportunities, but the long-term outlook is uncertain. Investors should be cautious and consider the high overall risk and lack of dividend yield before making any decisions. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.115121 |
| AutoARIMA | 0.115121 |
| MSTL | 0.121946 |
| AutoTheta | 0.249970 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 12.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.039 |
| Excess Kurtosis | 0.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 108.094 |
| Revenue per Share | 2.267 |
| Market Cap | 75,998,048 |
| Forward P/E | -1.34 |
| Beta | 1.45 |
| Profit Margins | 10.77% |
| Website | https://www.fortressbiotech.com |
As of April 11, 2026, 3:10 p.m. EDT: Options speculators are showing mixed signals. Calls have higher open interest and volume, particularly for strikes above the current price, indicating potential bullish sentiment. However, puts also show significant open interest, especially around the current price level, suggesting some bearish positioning. The IV on calls is higher, indicating higher volatility expectations, while puts have lower IV, which may imply less bearish sentiment. Overall, the options market is not clear on direction, but there is a notable presence of both bullish and bearish bets.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5733334 |
| Address1 | 1,111 Kane Concourse |
| Address2 | Suite 301 |
| All Time High | 190.5 |
| All Time Low | 1.24 |
| Ask | 2.38 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 508,070 |
| Average Daily Volume3 Month | 762,901 |
| Average Volume | 762,901 |
| Average Volume10Days | 508,070 |
| Beta | 1.448 |
| Bid | 2.34 |
| Bid Size | 3 |
| Board Risk | 10 |
| Book Value | 1.59 |
| City | Bay Harbor Islands |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.36 |
| Current Ratio | 2.49 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.435 |
| Day Low | 2.33 |
| Debt To Equity | 108.094 |
| Display Name | Fortress Biotech |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -65,560,000 |
| Ebitda Margins | -1.03633 |
| Enterprise To Ebitda | -1.161 |
| Enterprise To Revenue | 1.204 |
| Enterprise Value | 76,146,048 |
| Eps Forward | -1.76 |
| Eps Trailing Twelve Months | -0.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.048 |
| Fifty Day Average Change | -0.6880002 |
| Fifty Day Average Change Percent | -0.22572185 |
| Fifty Two Week Change Percent | 57.33334 |
| Fifty Two Week High | 4.53 |
| Fifty Two Week High Change | -2.1700003 |
| Fifty Two Week High Change Percent | -0.47902873 |
| Fifty Two Week Low | 1.45 |
| Fifty Two Week Low Change | 0.90999985 |
| Fifty Two Week Low Change Percent | 0.62758607 |
| Fifty Two Week Range | 1.45 - 4.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,321,540,200,000 |
| Float Shares | 22,145,703 |
| Forward Eps | -1.76 |
| Forward P E | -1.340909 |
| Free Cashflow | -47,286,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 78 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.48113 |
| Gross Profits | 30,437,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22690001 |
| Held Percent Institutions | 0.18228 |
| Implied Shares Outstanding | 32,202,564 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,696,896,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. |
| Long Name | Fortress Biotech, Inc. |
| Market | us_market |
| Market Cap | 75,998,048 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_61731337 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,882,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 75,998,051 |
| Number Of Analyst Opinions | 2 |
| Open | 2.37 |
| Operating Cashflow | -65,777,000 |
| Operating Margins | -0.29784 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 781 652 4500 |
| Post Market Change | 0.0078001022 |
| Post Market Change Percent | 0.33051282 |
| Post Market Price | 2.3678 |
| Post Market Time | 1,776,462,281 |
| Previous Close | 2.35 |
| Price Hint | 4 |
| Price To Book | 1.4842767 |
| Price To Sales Trailing12 Months | 1.2013222 |
| Profit Margins | 0.10773 |
| Quick Ratio | 2.198 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.425532 |
| Regular Market Day High | 2.435 |
| Regular Market Day Low | 2.33 |
| Regular Market Day Range | 2.33 - 2.435 |
| Regular Market Open | 2.37 |
| Regular Market Previous Close | 2.35 |
| Regular Market Price | 2.36 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 416,367 |
| Return On Assets | -0.26617 |
| Return On Equity | -1.0874 |
| Revenue Growth | 0.063 |
| Revenue Per Share | 2.267 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 32,202,564 |
| Shares Percent Shares Out | 0.1354 |
| Shares Short | 4,361,750 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,484,322 |
| Short Name | Fortress Biotech, Inc. |
| Short Percent Of Float | 0.168 |
| Short Ratio | 9.36 |
| Source Interval | 15 |
| State | FL |
| Symbol | FBIO |
| Target High Price | 17.0 |
| Target Low Price | 4.5 |
| Target Mean Price | 10.75 |
| Target Median Price | 10.75 |
| Total Cash | 79,381,000 |
| Total Cash Per Share | 2.465 |
| Total Debt | 67,216,000 |
| Total Revenue | 63,262,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.89325 |
| Two Hundred Day Average Change | -0.5332501 |
| Two Hundred Day Average Change Percent | -0.18430834 |
| Type Disp | Equity |
| Volume | 416,367 |
| Website | https://www.fortressbiotech.com |
| Zip | 33,154 |